122 related articles for article (PubMed ID: 2418292)
1. Acute effect of ketanserin on the leg perfusion assessed by Doppler pressure measurements and 201Tl scintigraphy in patients with intermittent claudication.
Bounameaux H; Devos P; Verhaeghe R
J Cardiovasc Pharmacol; 1985; 7(6):1083-6. PubMed ID: 2418292
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
De Cree J; Leempoels J; Geukens H; Verhaegen H
Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
Bounameaux H; Holditch T; Hellemans H; Berent A; Verhaeghe R
Lancet; 1985 Dec; 2(8467):1268-71. PubMed ID: 2866336
[TBL] [Abstract][Full Text] [Related]
4. Ketanserin in intermittent claudication. A double-blind placebo-controlled study.
Clement DL; Duprez D; Van Wassenhove A; Brusselmans F
Int Angiol; 1989; 8(2):92-6. PubMed ID: 2681451
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy.
Circulation; 1989 Dec; 80(6):1544-8. PubMed ID: 2688971
[TBL] [Abstract][Full Text] [Related]
6. A quantitative assessment of scintigraphy of the legs using 201Tl.
Hamanaka D; Odori T; Maeda H; Ishii Y; Hayakawa K; Torizuka K
Eur J Nucl Med; 1984; 9(1):12-6. PubMed ID: 6230235
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication.
Walden R; Bass A; Rabi I; Adar R
J Cardiovasc Surg (Torino); 1991; 32(6):737-40. PubMed ID: 1752890
[TBL] [Abstract][Full Text] [Related]
8. Effect of ketanserin on macrocirculatory and microcirculatory blood flow in patients with intermittent claudication. A prospective randomized study.
Beckers RC; Jörning PJ; Slaaf DW; Reneman RS; Jacobs MJ
Eur J Clin Pharmacol; 1989; 37(3):295-6. PubMed ID: 2693113
[TBL] [Abstract][Full Text] [Related]
9. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled trial of ketanserin in the treatment of intermittent claudication.
Cameron HA; Waller PC; Ramsay LE
Angiology; 1987 Jul; 38(7):549-55. PubMed ID: 3304029
[TBL] [Abstract][Full Text] [Related]
11. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
[TBL] [Abstract][Full Text] [Related]
12. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies.
Clement DL; Duprez D
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S89-95. PubMed ID: 2446082
[TBL] [Abstract][Full Text] [Related]
13. Regional distribution of 201Tl during one-leg exercise: comparison with leg blood flow by plethysmography.
Seto H; Kageyama M; Futatsuya R; Shimizu M; Watanabe N; Wu Y; Kakishita M
Nucl Med Commun; 1993 Sep; 14(9):810-3. PubMed ID: 8233247
[TBL] [Abstract][Full Text] [Related]
14. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
[TBL] [Abstract][Full Text] [Related]
15. Controlled trial of suloctidil in intermittent claudication.
Verhaeghe R; Van Hoof A; Beyens G
J Cardiovasc Pharmacol; 1981; 3(2):279-86. PubMed ID: 6166799
[TBL] [Abstract][Full Text] [Related]
16. A double-blind trial of suloctidil v. placebo in intermittent claudication.
Jones NA; De Haas H; Zahavi J; Kakkar VV
Br J Surg; 1982 Jan; 69(1):38-40. PubMed ID: 6274471
[TBL] [Abstract][Full Text] [Related]
17. Simultaneouus flow and pressure measurements in intermittent claudication.
Lewis JD; Papathanaiou C; Yao ST; Eastcott HH
Br J Surg; 1972 Jun; 59(6):418-22. PubMed ID: 5031187
[No Abstract] [Full Text] [Related]
18. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
De Cree J; Leempoels J; Geukens H; Verhaegen H
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
[TBL] [Abstract][Full Text] [Related]
19. Whole-body 201Tl scintigraphy during one-leg exercise and at rest in normal subjects: estimation of regional blood flow changes.
Seto H; Kageyama M; Nomura K; Watanabe N; Inagaki S; Kakishita M; Wada O; Asanoi H
Nucl Med Commun; 1995 Aug; 16(8):661-6. PubMed ID: 7491178
[TBL] [Abstract][Full Text] [Related]
20. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study.
Brevetti G; Attisano T; Perna S; Rossini A; Policicchio A; Corsi M
Angiology; 1989 Oct; 40(10):857-62. PubMed ID: 2679240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
